Durvalumab
- PDF / 170,050 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 113 Downloads / 128 Views
1 S
Durvalumab Retinal vasculitis: case report
A 64-year-old man developed retinal vasculitis during treatment with durvalumab for non-small-cell lung carcinoma. The man, who had non-small-cell lung carcinoma, presented to the hospital due to sudden left eye vision loss. It was reported that he had been receiving treatment with durvalumab 1125mg every three weeks [route not stated] for 20 months. His serology testing showed negative results for human immu-nodeficiency virus, herpes viruses and T. pallidum. His best-corrected visual acuity was found to be 20/20 in the right-side eye and counting fingers in the left-sided eye. His fundoscopy revealed papillitis, intraretinal hemorrhages, severe cystoid macular oedema, dot and blot haemorrhages and mild white sheath in his macular vascular branches. His posterior optical coherence tomography showed cystoid oedema of the macula along with hyperreflective material secondary to the severe inflammation of retina and vitreous hyperreflective foci. Vascular leakage and tertiary branch phlebitis was observed upon fundus fluorescein angiography. Based on these findings and clinical presentation retinal vasculitis secondary to durvalumab was considered [duration of treatment to reaction onset not stated]. Therefore, the man was admitted and treatment with methylprednisolone followed by prednisone was commenced. Twenty four hours after the admission, improvement in his visual symptoms was observed. Eventually, his visual acuity improved to 20/25 at the 2 months follow-up visit. His optical coherence tomography showed reduction of the macular oedema and repeated angiography revealed resolution of his ocular vasculitis. At the one year follow-up visit, he had complete resolution of the retinal vasculitis, and he was taking durvalumab without any adverse effect. Andrade AR, et al. Retinal Vasculitis Secondary to Durvalumab. Case Reports in Ophthalmology 11: 161-166, No. 2, 2020. Available from: URL: http:// doi.org/10.1159/000507609
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803517249
Reactions 28 Nov 2020 No. 1832
Data Loading...
